Pramlintide vs Survodutide
A side-by-side research comparison of Pramlintide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pramlintide | Survodutide |
|---|---|---|
| Full name | Pramlintide (Symlin) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 3949.4 Da | 4,500 Da (approximate) |
| Half-life | ~48 minutes | 5-7 days |
| Bioavailability | Subcutaneous injection | High (SubQ) |
| Typical dose | 15-120 mcg before meals | 0.6-6.0 mg |
| Frequency | Before major meals | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
Pramlintide reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.